MIT and Harvard sign genome licensing deal

05-12-2014

MIT and Harvard sign genome licensing deal

f11photo / Shutterstock.com

US research centre the Broad Institute of Massachusetts Institute of Technology and Harvard has entered into a worldwide licensing deal with Editas Medicines, granting it access to IP covering genome technology and human therapeutic applications.


CRISPR-Cas9, Broad Institute, IP portfolio, MIT, Harvard

LSIPR